NYSE American · Biotechnology · USD
Theriva Biologics, Inc. (TOVX) Stock Analysis
Theriva Biologics, Inc. (TOVX) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
TOVX Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.21
- Previous Close
- $0.21
- Day's Range
- 0.20–0.22
- 52-Week Range
- 0.16–0.85
- Volume
- 694.24K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.19
Valuation
- Market Cap
- $9.02M
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 30.07
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$23.74M
- Shares Outstanding
- 45.89M
- 1-Year Return
- −34.47%
Dividend and dates
- Avg Volume
- 514.13K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, TOVX closed at $0.20, −34.47% over 1 year.
Theriva Biologics, Inc. (TOVX) has a market capitalization of $9.02M.
In fiscal 2025, TOVX reported revenue of $0.00.
TOVX Stock Return by Calendar Year
Theriva Biologics, Inc. (TOVX) 10-year return: what $10,000 became
- 1 year
- $10,000 $6,553
- −34.47%
- 5 years
- $10,000 $18
- −99.82%
- 10 years
- $10,000 $0.14
- −99.999%
If you had invested $10,000 in Theriva Biologics, Inc. (TOVX) 10 years ago, at the close on October 21, 2016, it would have been worth $0.14 at the close on October 21, 2026: −99.999% in total, −67.29% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −6.38% |
| 2025 | −88.00% |
| 2024 | −83.72% |
| 2023 | −4.44% |
| 2022 | −83.33% |
| 2021 | −28.95% |
| 2020 | −25.49% |
| 2019 | −8.93% |
| 2018 | −96.86% |
| 2017 | −32.89% |
| 2016 (partial year) | −54.76% |
As of October 21, 2026.
TOVX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$23.74M | — |
| 2024 | $0.00 | −$25.65M | — |
| 2023 | $0.00 | −$18.35M | — |
| 2022 | $0.00 | −$19.69M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$24.05M | −$23.74M | — |
| 2024 | $0.00 | — | −$19.43M | −$25.65M | — |
| 2023 | $0.00 | — | −$21.43M | −$18.35M | — |
| 2022 | $0.00 | — | −$21.58M | −$19.69M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
TOVX Valuation vs Biotechnology Median
Median of 608 stocks| Metric | TOVX | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 30.07 | 13.30 | 126% above |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
YahooTheriva Biologics Q2 EPS $(0.07) Misses $(0.05) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B